|本期目录/Table of Contents|

[1]李静静,许金花,吴国峰,等.伏美替尼一线治疗EGFR突变晚期NSCLC脑转移的临床分析[J].中华肺部疾病杂志,2024,(03):426-429.[doi:10.3877/cma.j.issn.1674-6902.2024.03.016 ]
点击复制

伏美替尼一线治疗EGFR突变晚期NSCLC脑转移的临床分析(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2024年03期
页码:
426-429
栏目:
临床研究
出版日期:
2024-06-25

文章信息/Info

Title:
-
作者:
李静静1; 许金花1; 吴国峰1; 任亚俊2; 张骞云1
061000 河北,沧州市中心医院呼吸与危重症医学科二科1、麻醉二科2
Author(s):
-
关键词:
晚期非小细胞肺癌;  伏美替尼;  表皮生长因子受体;  敏感突变;  脑转移
Keywords:
-
分类号:
R734.2
DOI:
10.3877/cma.j.issn.1674-6902.2024.03.016
摘要:
目的 分析伏美替尼一线治疗表皮生长因子受体(epidermal growth factor receptor, EGFR)突变晚期晚期非小细胞肺癌(non small-cell lung cancer, NSCLC)脑转移的临床效果。方法 选取2020年6月至2022年4月我院收治的47例EGFR突变晚期NSCLC脑转移患者,对照组25例采取脑放疗治疗,观察组22例联合使用伏美替尼一线治疗。比较两组治疗效果。结果 观察组颅内疾病控制率(intracranial disease control rate, IDCR)86.36%高于对照组68.00%(P>0.05); 观察组客观缓解率(objective mitigation rate, ORR)68.18%高于对照组36.00%(P<0.05)。治疗3个月,观察组血清癌胚抗原(serum carcinoembryonic antigen, CEA)(6.52±0.78)ng/ml、血管内皮生长因子(vascular endothelial growth factor, VEGF)(82.63±12.02)μg/L低于对照组(12.63±1.47)μg/L、(104.24±14.84)μg/L(P<0.05)。观察组低钾血症发生率31.82%、食欲下降发生率36.36%高于对照组4.00%、8.00%(P<0.05)。1例患者退出,中途因家庭地址更换、失联等因素脱落5例,观察组19例、对照组22例完成最终随访。观察组生存率84.21%(16/19)高于对照组50.00%(11/22)(P<0.05)。结论 对EGFR敏感突变的晚期NSCLC脑转移患者采取伏美替尼一线治疗,可明显改善患者血清CEA、VEGF水平。
Abstract:
-

参考文献/References:

1 Kang J, Zhang C, Zhong WZ. Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art[J]. Cancer Commun(Lond), 2021, 41(4): 287-302.
2 Marks JA, Wilgucki M, Liu SV, et al. Antibody-drug conjugates in non-small cell lung cancer: Emergence of a novel therapeutic class[J]. Curr Oncol Rep, 2022, 24(12): 1829-1841.
3 Veluswamy R, Mack PC, Houldsworth J, et al. KRAS G12C-mutant non-small cell lung cancer: Biology, developmental therapeutics, and molecular testing[J]. J Mol Diagn, 2021, 23(5): 507-520.
4 Shah MP, Neal JW. Targeting acquired and intrinsic resistance mechanisms in epidermal growth factor receptor mutant non-small-cell lung cancer[J]. Drugs, 2022, 82(6): 649-662.
5 朱玲玲, 王 艇, 伍 娟, 等. 2023年第3版《NCCN肿瘤临床实践指南:非小细胞肺癌》更新解读[J]. 中国肺癌杂志, 2023, 26(6): 407-415.
6 Sabbah DA, Hajjo R, Sweidan K. Review on epidermal growth factor receptor(EGFR)structure, signaling pathways, interactions, and recent updates of EGFR inhibitors[J]. Curr Top Med Chem, 2020, 20(10): 815-834.
7 左 强, 江国强, 方 芳, 等. 伏美替尼治疗EGFR突变阳性非小细胞肺癌EGFR-TKI耐药患者的临床观察[J]. 中国现代医学杂志, 2022, 32(14): 30-34.
8 王 敏, 杨雪光, 徐 蓉, 等. 上海金山地区利伐沙班出凝血异常药物不良反应/事件临床分析[J]. 海南医学, 2023, 34(8): 1156-1159.
9 Higgins KA, Puri S, Gray JE. Systemic and radiation therapy approaches for locally advanced non-small-cell lung cancer[J]. J Clin Oncol, 2022, 40(6): 576-585.
10 李咏生, 孙建国, 李梦侠. 重庆肺癌精准治疗协作组(CPLOG).第三代EGFR-TKI耐药后诊疗策略专家共识[J/CD]. 中华肺部疾病杂志(电子版), 2023, 16(2): 145-155.
11 Muthusamy B, Patil PD, Pennell NA. Perioperative systemic therapy for resectable non-small cell lung cancer[J]. J Natl Compr Canc Netw, 2022, 20(8): 953-961.
12 Zheng X, Luo J, Liu W, et al. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation[J]. Drugs Today(Barc), 2022, 58(4): 175-185.
13 Xiang Y, Zhang S, Fang X, et al. Therapeutic advances of rare ALK fusions in non-small cell lung cancer[J]. Curr Oncol. 2022, 29(10): 7816-7831.
14 Ajimizu H, Ozasa H, Sato S, et al. Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer[J]. Sci Rep, 2021, 11(1): 23677.
15 Mielgo-Rubio X, Martín M, Remon J, et al. Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges[J]. Future Oncol, 2021, 17(30): 4011-4025.
16 Lim JU. Overcoming osimertinib resistance in advanced non-small cell lung cancer[J]. Clin Oncol(R Coll Radiol), 2021, 33(10): 619-626.
17 Gaebe K, Li AY, Park A, et al. Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis[J]. Lancet Oncol, 2022, 23(7): 931-939.
18 Matsoukas S, Bageac DV, DeLeacy R, et al. De novo brain AVM following radiotherapy for cerebral cavernous malformation in a child: A 15-year clinical course[J]. Neuroradiol J, 2022, 35(4): 533-538.
19 蒋兴然, 路 军, 顾亚娟, 等. 非小细胞肺癌患者循环肿瘤细胞第7, 8号染色体多体及其与组织中表皮生长因子受体基因突变的相关性[J]. 中华病理学杂志, 2021, 50(5): 447-452.
20 Sun X, Xu S, Yang Z, et al. Epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review(2014-present)[J]. Expert Opin Ther Pat, 2021, 31(3): 223-238.
21 Hosomi Y, Morita S, Sugawara S, et al.Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 Study[J]. J Clin Oncol, 2020, 38(2): 115-123.
22 Ruiz-Camps I, Aguilar-Company J. Epidermal growth factor receptor inhibitors and other tyrosine kinase inhibitors for solid tumors[J]. Infect Dis Clin North Am, 2020, 34(2): 257-270.
23 王燕山, 牛 犁, 李小英. 表皮生长因子受体酪氨酸激酶抑制剂靶向治疗对老年晚期肺癌患者肿瘤标志物的影响[J]. 重庆医学, 2022, 51(1): 280-282.
24 He J, Huang Z, Han L, et al. Mechanisms and management of 3rdgeneration EGFRTKI resistance in advanced nonsmall cell lung cancer(Review)[J]. Int J Oncol, 2021, 59(5): 90.
25 Liu Y, Li Z, Zhang M, et al. Rolling-translated EGFR variants sustain EGFR signaling and promote glioblastoma tumorigenicity[J]. Neuro Oncol, 2021, 23(5): 743-756.
26 朱燕娟, 曲 鑫, 陈惠惠, 等. 非小细胞肺癌热毒证与基因突变及表皮生长因子酪氨酸激酶抑制剂疗效的相关性[J]. 中华中医药杂志, 2022, 37(8): 4756-4760.
27 Nan X, Li X, Wu Y, et al. synthesis and biological evaluation of sulfonylamidines as potent c-Met inhibitors by enhancing hydrophobic interaction[J]. Org Biomol Chem, 2023, 21(36): 7459-7466.
28 Fujino T, Suda K, Koga T, et al. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation[J]. J Hematol Oncol, 2022, 15(1): 79.

备注/Memo

备注/Memo:
基金项目: 河北省医学科学研究重点课题项目(20200102)
沧州市重点研发计划指导项目(204106114)
通信作者: 张骞云, Email: zhangqianyun001@163.com
更新日期/Last Update: 2024-06-25